December 17, 2024 01:44 (IST)
Follow us:
facebook-white sharing button
twitter-white sharing button
instagram-white sharing button
youtube-white sharing button
GRAP 4 restrictions reimposed in Delhi as air quality dips to 'severe' category | 39 ministers included in Devendra Fadnavis-led Maharashtra cabinet | People who raise questions on EVMs should show how they can be hacked: TMC trashes Congress claims | Bangladesh likely to hold national polls in late 2025 or early 2026, says Yunus in Victory Day speech | Constitution stood test of time: Nirmala Sitharaman in Rajya Sabha | PM Museum requests Rahul Gandhi to return Pandit Nehru's historical letters | Indian tabla maestro Zakir Hussain dies at 73 in San Francisco, confirms family | Kolkata woman strangled, beheaded and chopped into pieces for refusing brother-in-law's advances | Arvind Kejriwal, CM Atishi to contest Delhi polls from current constituencies | Atul Subhash suicide case: Wife Nikita, her mother and brother arrested

Sanofi India Limited appoints N. Rajaram as Managing Director

| @indiablooms | Dec 16, 2017, at 03:47 am

Mumbai/Kolkata,  Dec 15 (IBNS): Sanofi India Limited (SIL) announced the elevation of N. Rajaram as the Managing Director of the company, with effect from 1st January, 2018. 

His appointment was approved by the Sanofi India Board of Directors earlier on Friday.

N. Rajaram joined Sanofi India in February 2014 and was appointed as Whole Time Director in October 2015.

Under his leadership, the company has doubled the size of its diabetes business and established a foothold in the consumer healthcare sector, while significantly transforming its market operations.      

Rajaram brings with him diverse experience of nearly two decades in the FMCG industry with Hindustan Unilever, and in the telecom industry with Airtel.

Rajaram holds a bachelor’s degree in Engineering from the Birla Institute of Technology & Science (BITS), Pilani, India and an MBA in International Business from the Indian Institute of Foreign Trade (IIFT), New Delhi. He is also an alumnus of the Advanced Managed Program of the Harvard Business School.     

N. Rajaram succeeds Dr. Shailesh Ayyangar who has been the Managing Director of Sanofi India Limited for over 12 years. Dr. Ayyangar will take up a new role in the Sanofi Asia region effective January 1st, 2018. He will also continue as a Non-Executive Director on the Board of Sanofi India Limited.

Speaking about the transition, Dr. Ayyangar said, “I am truly grateful for the trust and confidence reposed on me over the years, by Sanofi India Limited’s shareholders, and other stakeholders including our employees and the senior leadership within Sanofi. It has been a real privilege to serve the Company and the country over a long period.”

He further added that, “While I am looking forward to taking on a new position in Sanofi Asia region, I am delighted to welcome N. Rajaram as the new Managing Director of SIL. This transition has been planned well in advance and I am very confident that under his leadership, SIL will scale greater heights of performance and continue to serve the patients of our country.”

Speaking on the occasion, N. Rajaram said, “Sanofi is a great global organization, which is focused on delivering transformational outcomes for patients based on scientific innovation and improved access to healthcare solutions. Our people have a contagious commitment and passion to empower the lives of the millions of patients we serve, making Sanofi an exciting and purposeful place to work. I’m thrilled to be part of this journey and hope to steer the Company through its next phase of growth."

Support Our Journalism

We cannot do without you.. your contribution supports unbiased journalism

IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.

Support objective journalism for a small contribution.